ARTICLE | Finance
Fresh off Lilly deal, AbCellera readies to deploy $105M to streamline antibody-based R&D
May 28, 2020 2:20 AM UTC
Days after expanding a deal with Eli Lilly, AbCellera has raised $105 million in a series B round to speed its partners’ path to the clinic by expanding its own R&D capabilities.
CEO Carl Hansen told BioCentury that AbCellera Biologics Inc. will use the untranched round to “double down on capacity, on people and on technology.” ...
BCIQ Company Profiles